DOCSLIB.ORG

Of 43 Reference ID: 4711890 FULL PRESCRIBING INFORMATION: CONTENTS*

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Of 43 Reference ID: 4711890 FULL PRESCRIBING INFORMATION: CONTENTS* HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use DOLUTEGRAVIR, EMTRICITABINE and TENOFOVIR -----------------------WARNINGS AND PRECAUTIONS------------------------ ALAFENAMIDE TABLETS safely and effectively. See full prescribing • Hypersensitivity reactions characterized by rash, constitutional findings, information for DOLUTEGRAVIR, EMTRICITABINE and and sometimes organ dysfunction, including liver injury have been TENOFOVIR ALAFENAMIDE TABLETS. reported. Discontinue dolutegravir, emtricitabine and tenofovir alafenamide tablets and other suspect agents immediately if signs or DOLUTEGRAVIR, EMTRICITABINE and TENOFOVIR symptoms of hypersensitivity reactions develop. (5.2) ALAFENAMIDE tablets, for oral use • Hepatotoxicity has been reported in patients receiving a dolutegravir- containing regimen. Monitoring for hepatotoxicity is recommended. WARNING: POST-TREATMENT ACUTE EXACERBATION OF (5.3) HEPATITIS B • Embryo-fetal toxicity may occur when used at the time of conception and in early pregnancy. An alternative treatment to dolutegravir, See full prescribing information for complete boxed warning. emtricitabine and tenofovir alafenamide tablets should be considered at the time of conception through the first trimester of pregnancy due to the Severe acute exacerbations of hepatitis B virus (HBV) have been reported risk of neural tube defects. Counsel adolescents and adults of in HBV-infected patients who have discontinued products containing childbearing potential to use effective contraception. (2.1, 5.4, 8.1, 8.3) emtricitabine and/or tenofovir disoproxil fumarate (TDF), and may occur • Immune reconstitution syndrome has been reported in patients treated with discontinuation of dolutegravir, emtricitabine and tenofovir with combination antiretroviral therapy. (5.6) alafenamide tablets. Hepatic function should be monitored closely in • New Onset or Worsening Renal Impairment. Assess serum creatinine, these patients. If appropriate, initiation of anti-hepatitis B therapy may estimated creatinine clearance, urine glucose, and urine protein when be warranted. (5.1) initiating dolutegravir, emtricitabine and tenofovir alafenamide tablets and during use on a clinically appropriate schedule in all patients. Also ----------------------------INDICATIONS AND USAGE--------------------------- assess serum phosphorus in patients with chronic kidney disease. (5.7) Dolutegravir, emtricitabine and tenofovir alafenamide tablets, a three-drug • Lactic acidosis/severe hepatomegaly with steatosis: Discontinue combination of dolutegravir (integrase strand transfer inhibitor [INSTI]), treatment in patients who develop symptoms or laboratory findings emtricitabine (FTC) and tenofovir alafenamide (TAF), both HIV nucleoside suggestive of lactic acidosis or pronounced hepatotoxicity. (5.8) analog reverse transcriptase inhibitors (NRTIs), is indicated as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients -------------------------------ADVERSE REACTIONS------------------------------ weighing at least 25 kg. (1) • Dolutegravir: The most common adverse reactions of moderate to severe Limitations of Use: intensity and incidence at least 2% (in those receiving dolutegravir in any one adult trial) are insomnia, fatigue, headache and diarrhea. (6.1) • Dolutegravir, emtricitabine and tenofovir alafenamide tablets alone is not • Emtricitabine and Tenofovir Alafenamide: Most common adverse recommended in patients with resistance-associated integrase reaction (incidence greater than or equal to 10% all grades) is nausea. substitutions or clinically suspected integrase strand transfer inhibitor (6.1) resistance because the dose of dolutegravir in dolutegravir, emtricitabine and tenofovir alafenamide tablets is insufficient in these subpopulations. To report SUSPECTED ADVERSE REACTIONS, contact Laurus See the dolutegravir prescribing information. (1) Generics Inc. at 1-833-3-LAURUS (1-833-352-8787) or FDA at 1-800- • Dolutegravir, emtricitabine and tenofovir alafenamide tablets is not FDA-1088 or www.fda.gov/medwatch. indicated for use as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in adults at high risk. -------------------------------DRUG INTERACTIONS------------------------------ Coadministration of dolutegravir, emtricitabine and tenofovir alafenamide ------------------------DOSAGE AND ADMINISTRATION---------------------- tablets with other drugs can alter the concentration of other drugs and other • Pregnancy Testing: Perform pregnancy testing before initiation of drugs may alter the concentration of dolutegravir, emtricitabine and tenofovir dolutegravir, emtricitabine and tenofovir alafenamide tablets in alafenamide tablets. The potential drug-drug interactions must be considered adolescents and adults of childbearing potential. (2.1, 5.4) prior to and during therapy. (4, 7, 12.3) • Testing: Prior to or when initiating dolutegravir, emtricitabine and tenofovir alafenamide tablets, test for hepatitis B virus infection. Prior to ------------------------USE IN SPECIFIC POPULATIONS----------------------- • or when initiating dolutegravir, emtricitabine and tenofovir alafenamide Pregnancy: An alternative treatment to dolutegravir, emtricitabine and tablets, and during treatment, assess serum creatinine, estimated tenofovir alafenamide tablets should be considered at the time of creatinine clearance, urine glucose, and urine protein in all patients as conception through the first trimester due to the risk of neural tube clinically appropriate. In patients with chronic kidney disease, also defects. (2.1, 5.4, 8.1) assess serum phosphorus. (2.1) • Lactation: Breastfeeding is not recommended due to the potential for • Recommended dosage: One tablet taken once daily in adults and HIV transmission. (8.2) pediatric patients weighing at least 25 kg. May be taken with or without • Females and males of reproductive potential: Pregnancy testing and food. (2.2) contraception are recommended in adolescents and adults of • Renal impairment: Dolutegravir, emtricitabine and tenofovir childbearing potential. (8.3) alafenamide tablets is not recommended in patients with estimated • Pediatrics: Not recommended for patients weighing less than 25 kg. creatinine clearance below 30 mL per minute. (2.3) (8.4) • Hepatic impairment: Dolutegravir, emtricitabine and tenofovir ----------------------DOSAGE FORMS AND STRENGTHS--------------------- alafenamide tablets is not recommended in patients with severe hepatic Tablets: 50 mg of dolutegravir, 200 mg of emtricitabine and 25 mg of impairment (Child-Pugh Score C). (8.7) tenofovir alafenamide (3) See 17 for PATIENT COUNSELING INFORMATION and FDA- -------------------------------CONTRAINDICATIONS------------------------------ approved patient labeling. • Previous hypersensitivity reaction to dolutegravir. (4) Issued: 12/2020 • Coadministration with dofetilide. (4) _______________________________________________________________________________________________________________________________________ Page 1 of 43 Reference ID: 4711890 FULL PRESCRIBING INFORMATION: CONTENTS* WARNING: POST-TREATMENT ACUTE EXACERBATION Dolutegravir, FTC, or TAF OF HEPATITIS B 7.3 Established and Other Potentially Significant Drug Interactions 1 INDICATIONS AND USAGE 7.4 Drugs without Clinically Significant Interactions with Dolutegravir, FTC, and TAF 2 DOSAGE AND ADMINISTRATION 7.5 Drugs Affecting Renal Function 2.1 Testing Prior to Initiation and During Treatment with Dolutegravir, Emtricitabine and Tenofovir Alafenamide 8 USE IN SPECIFIC POPULATIONS Tablets 8.1 Pregnancy 2.2 Recommended Dosage in Adults and Pediatric Patients 8.2 Lactation Weighing at Least 25 kg (55 lbs) 8.3 Females and Males of Reproductive Potential 2.3 Not Recommended in Patients with Severe Renal 8.4 Pediatric Use Impairment 8.5 Geriatric Use 2.4 Not Recommended in Patients with Severe Hepatic 8.6 Renal Impairment Impairment 8.7 Hepatic Impairment 3 DOSAGE FORMS AND STRENGTHS 10 OVERDOSAGE 4 CONTRAINDICATIONS 11 DESCRIPTION 5 WARNINGS AND PRECAUTIONS 12 CLINICAL PHARMACOLOGY 5.1 Severe Acute Exacerbation of Hepatitis B in Patients with 12.1 Mechanism of Action HBV Infection 12.2 Pharmacodynamics 5.2 Hypersensitivity Reactions 12.3 Pharmacokinetics 5.3 Hepatotoxicity 12.4 Microbiology 5.4 Embryo-Fetal Toxicity 5.5 Risk of Adverse Reactions or Loss of Virologic Response 13 NONCLINICAL TOXICOLOGY Due to Drug Interactions 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility 5.6 Immune Reconstitution Syndrome 13.2 Animal Toxicology and/or Pharmacology 5.7 New Onset or Worsening Renal Impairment 5.8 Lactic Acidosis and Severe Hepatomegaly with Steatosis 14 CLINICAL STUDIES 14.1 Adult Subjects 6 ADVERSE REACTIONS 14.2 Pediatric Subjects 6.1 Clinical Trials Experience 6.2 Postmarketing Experience 16 HOW SUPPLIED/STORAGE AND HANDLING 7 DRUG INTERACTIONS 17 PATIENT COUNSELING INFORMATION 7.1 Effect of Dolutegravir on the Pharmacokinetics of Other Agents *Sections or subsections omitted from the full prescribing 7.2 Effect of Other Agents on the Pharmacokinetics of information are not listed. Page 2 of 43 Reference ID: 4711890 FULL PRESCRIBING INFORMATION WARNING: POST-TREATMENT ACUTE EXACERBATION OF HEPATITIS B Severe acute exacerbations of hepatitis B virus (HBV) have been reported in HBV-infected patients who have discontinued products containing emtricitabine (FTC) and/or tenofovir disoproxil fumarate (TDF), and may occur with discontinuation of dolutegravir, emtricitabine
Load more

Recommended publications
  • Effects of Enzyme Inducers Efavirenz and Tipranavir/Ritonavir on the Pharmacokinetics of the HIV Integrase Inhibitor Dolutegravir
    Eur J Clin Pharmacol (2014) 70:1173–1179 DOI 10.1007/s00228-014-1732-8 CLINICAL TRIAL Effects of enzyme inducers efavirenz and tipranavir/ritonavir on the pharmacokinetics of the HIV integrase inhibitor dolutegravir Ivy Song & Julie Borland & Shuguang Chen & Phyllis Guta & Yu Lou & David Wilfret & Toshihiro Wajima & Paul Savina & Amanda Peppercorn & Stephen Castellino & David Wagner & Louise Hosking & Michael Mosteller & Justin P.Rubio & Stephen C. Piscitelli Received: 7 May 2014 /Accepted: 11 August 2014 /Published online: 23 August 2014 # The Author(s) 2014. This article is published with open access at Springerlink.com Abstract study due to increases in alanine aminotransferase that were Purpose Dolutegravir (DTG) is an unboosted, integrase in- considered related to TPV/r. Co-administration with EFV hibitor for the treatment of HIV infection. Two studies evalu- resulted in decreases of 57, 39 and 75 % in DTG AUC(0–τ), ated the effects of efavirenz (EFV) and tipranavir/ritonavir Cmax and Cτ, respectively. Co-administration with TPV/r re- (TPV/r) on DTG pharmacokinetics (PK) in healthy subjects. sulted in decreases of 59, 46 and 76 % in DTG AUC(0–τ), Cmax Methods The first study was an open-label crossover where and Cτ, respectively. 12 subjects received DTG 50 mg every 24 hours (q24h) for Conclusions Given the reductions in exposure and PK/ 5 days, followed by DTG 50 mg and EFV 600 mg q24h for pharmacodynamic relationships in phase II/III trials, DTG 14 days. The second study was an open-label crossover where should be given at an increased dose of 50 mg twice daily 18 subjects received DTG 50 mg q24h for 5 days followed by when co-administered with EFV or TPV/r, and alternative TPV/r 500/200 mg every 12 hours (q12h) for 7 days and then regimens without inducers should be considered in integrase DTG 50 mg q24h and TPV/r 500/200 mg q12h for a further inhibitor-resistant patients.
    [Show full text]
  • Revised 4/1/2021 GEORGIA MEDICAID FEE-FOR-SERVICE HIV
    GEORGIA MEDICAID FEE-FOR-SERVICE HIV-AIDS PA SUMMARY Preferred (may not be all inclusive) Non-Preferred Abacavir generic Abacavir/lamivudine/zidovudine generic Abacavir/lamivudine generic Aptivus (tipranavir) Complera (emtricitabine/rilpivirine/tenofovir disoproxil Atazanavir capsules generic fumarate) Atripla (efavirenz/emtricitabine/tenofovir disoproxil Crixivan (indinavir) fumarate) Biktarvy (bictegravir/emtricitabine/tenofovir Delstrigo (doravirine/lamivudine/tenofovir disoproxil alafenamide) fumarate) Cimduo (lamivudine/tenofovir disoproxil fumarate) Fuzeon (enfuvirtide) Descovy (emtricitabine/tenofovir alafenamide) Intelence (etravirine) Dovato Invirase (saquinavir) Edurant (rilpivirine)* Lexiva (fosamprenavir) Efavirenz tablets generic Nevirapine extended-release generic Emtriva (emtricitabine) Norvir Powder (ritonavir) Epivir solution (lamivudine) Pifeltro (doravirine) Evotaz (atazanavir/cobicistat)* Reyataz Powder (atazanavir) Genvoya (elvitegravir/cobicistat/emtricitabine/ Ritonavir tablets generic tenofovir alafenamide) Isentress and Isentress HD (raltegravir)* Rukobia (fostemsavir) Juluca (dolutegravir/rilpivirine) Selzentry (maraviroc) Kaletra (lopinavir/ritonavir) Stavudine generic^ Stribild (elvitegravir/cobicistat/emtricitabine/ tenofovir Lamivudine generic disoproxil fumarate) Symfi (efavirenz 600 mg/lamivudine/tenofovir Lamivudine/zidovudine generic disoproxil fumarate) Symfi Lo (efavirenz 400 mg/lamivudine/tenofovir Nevirapine immediate-release tablets generic disoproxil fumarate) Norvir (ritonavir) Temixys (lamivudine/tenofovir
    [Show full text]
  • Truvada (Emtricitabine / Tenofovir Disoproxil)
    Pre-exposure Prophylaxis (2.3) HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Recommended dose in HIV-1 uninfected adults: One tablet TRUVADA safely and effectively. See full prescribing information (containing 200 mg/300 mg of emtricitabine and tenofovir for TRUVADA. disoproxil fumarate) once daily taken orally with or without food. (2.3) TRUVADA® (emtricitabine/tenofovir disoproxil fumarate) tablets, for oral use Recommended dose in renally impaired HIV-uninfected Initial U.S. Approval: 2004 individuals: Do not use TRUVADA in HIV-uninfected individuals if CrCl is below 60 mL/min. If a decrease in CrCl is observed in WARNING: LACTIC ACIDOSIS/SEVERE HEPATOMEGALY WITH uninfected individuals while using TRUVADA for PrEP, evaluate STEATOSIS, POST-TREATMENT ACUTE EXACERBATION OF potential causes and re-assess potential risks and benefits of HEPATITIS B, and RISK OF DRUG RESISTANCE WITH USE OF continued use. (2.4) TRUVADA FOR PrEP IN UNDIAGNOSED HIV-1 INFECTION -----------------------DOSAGE FORMS AND STRENGTHS-------------------­ See full prescribing information for complete boxed warning. Tablets: 200 mg/300 mg, 167 mg/250 mg, 133 mg/200 mg, and 100 Lactic acidosis and severe hepatomegaly with steatosis, mg/150 mg of emtricitabine and tenofovir disoproxil fumarate . (3) including fatal cases, have been reported with the use of nucleoside analogs, including VIREAD, a component of TRUVADA. (5.1) --------------------------------CONTRAINDICATIONS-----------------------------­ TRUVADA is not approved for the treatment of chronic Do not use TRUVADA for pre-exposure prophylaxis in individuals with hepatitis B virus (HBV) infection. Severe acute unknown or positive HIV-1 status. TRUVADA should be used in exacerbations of hepatitis B have been reported in patients HIV-infected patients only in combination with other antiretroviral coinfected with HIV-1 and HBV who have discontinued agents.
    [Show full text]
  • Page: Treatment-Drugs
    © National HIV Curriculum PDF created September 29, 2021, 5:12 am Darunavir-Cobicistat-Tenofovir alafenamide-Emtricitabine (Symtuza) Table of Contents Darunavir-Cobicistat-Tenofovir alafenamide-Emtricitabine Symtuza Summary Drug Summary Key Clinical Trials Key Drug Interactions Drug Summary The fixed-dose combination tablet darunavir-cobicistat-tenofovir alafenamide-emtricitabine is a single-tablet regimen that can be considered for treatment-naïve or certain treatment-experienced adults living with HIV. This single-tablet regimen offers a one pill daily regimen with high barrier to resistance (due to the darunavir- cobicistat), with potentially less renal and bone toxicity as compared to regimens that include tenofovir DF; however, it has potential gastrointestinal adverse effects and drug-drug interactions, primarily due to the cobicistat component. In clinical trials, darunavir-cobicistat-tenofovir alafenamide-emtricitabine was compared to darunavir-cobicistat plus tenofovir DF-emtricitabine as initial therapy for treatment-naïve individuals and found to be equally effective in terms of viral suppression. A switch to the fixed-dose combination tablet was also compared to continuing a boosted protease inhibitor plus tenofovir DF- emtricitabine and again determined to have equivalent efficacy. The FDA has approved darunavir-cobicistat- tenofovir alafenamide-emtricitabine as a complete regimen for treatment-naïve individuals or treatment- experienced individuals who have a suppressed HIV RNA level on a stable regimen for at least 6 months and no resistance to darunavir or tenofovir. Key Clinical Trials A phase 3 trial in treatment-naïve individuals compared the fixed-dose single-tablet regimen darunavir- cobicistat-tenofovir alafenamide-emtricitabine with the regimen darunavir-cobicistat plus tenofovir DF- emtricitabine emtricitabine [AMBER].
    [Show full text]
  • Download Article PDF/Slides
    New Antiretrovirals in Development: Reprinted from The PRN Notebook,™ june 2002. Dr. James F. Braun, Editor-in-Chief. Tim Horn, Executive Editor. Published in New York City by the Physicians’ Research Network, Inc.,® John Graham Brown, Executive Director. For further information and other articles The View in 2002 available online, visit http://www.PRN.org All rights reserved. © june 2002. Roy “Trip” Gulick, md, mph Associate Professor of Medicine, Weill Medical College of Cornell University Director, Cornell Clinical Trials Unit, New York, New York Summary by Tim Horn Edited by Scott Hammer, md espite the fact that 16 antiretro- tiviral activity of emtricitabine was estab- Preliminary results from two random- virals are approved for use in the lished, with total daily doses of 200 mg or ized studies—FTC-302 and FTC-303—were United States, there is an indis- more producing the greatest median viral reported by Dr. Charles van der Horst and putable need for new anti-hiv com- load suppression: 1.72-1.92 log. Based on his colleagues at the 8th croi, held in Feb- pounds that have potent and these data, a once-daily dose of 200 mg ruary 2001 in Chicago (van der Horst, durable efficacy profiles, unique re- was selected for further long-term clinical 2001). FTC-302 was a blinded comparison sistance patterns, patient-friendly dosing study. “This is what we’re looking forward of emtricitabine and lamivudine, both in schedules, and minimal toxicities. To pro- to with emtricitabine,” commented Dr. combination with stavudine (Zerit) and vide prn with a glimpse of drugs current- Gulick.
    [Show full text]
  • Product Monograph for CELSENTRI
    PRODUCT MONOGRAPH PrCELSENTRI maraviroc Tablets 150 and 300 mg CCR5 antagonist ViiV Healthcare ULC 245, boulevard Armand-Frappier Laval, Quebec H7V 4A7 Date of Revision: July 05, 2019 Submission Control No: 226222 © 2019 ViiV Healthcare group of companies or its licensor. Trademarks are owned by or licensed to the ViiV Healthcare group of companies. Page 1 of 60 Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION.........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE..............................................................................3 CONTRAINDICATIONS ...................................................................................................3 WARNINGS AND PRECAUTIONS..................................................................................4 ADVERSE REACTIONS....................................................................................................9 DRUG INTERACTIONS ..................................................................................................19 DOSAGE AND ADMINISTRATION..............................................................................28 OVERDOSAGE ................................................................................................................31 ACTION AND CLINICAL PHARMACOLOGY ............................................................31 STORAGE AND STABILITY..........................................................................................36
    [Show full text]
  • Recommendations on First and Second Line Antiretroviral Regimens
    POLICY BRIEF UPDATE OF RECOMMENDATIONS ON FIRST- AND SECOND-LINE ANTIRETROVIRAL REGIMENS JULY 2019 HIV TREATMENT WHO/CDS/HIV/19.15 © World Health Organization 2019 Some rights reserved. This work is available under the Creative Commons Attribution- NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/ licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. Update of recommendations on first- and second-line antiretroviral regimens. Geneva, Switzerland: World Health Organization; 2019 (WHO/CDS/HIV/19.15). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data. CIP data are available at http://apps.who.int/iris. Sales, rights and licensing.
    [Show full text]
  • Vitekta Pi.Pdf
    HIGHLIGHTS OF PRESCRIBING INFORMATION -----------------------DOSAGE FORMS AND STRENGTHS-------------------- These highlights do not include all the information needed to use Tablets: 85 mg and 150 mg (3) VITEKTA safely and effectively. See full prescribing information for VITEKTA. --------------------------------CONTRAINDICATIONS------------------------------ VITEKTA® (elvitegravir) tablets, for oral use There are no contraindications to VITEKTA. (4) Initial U.S. Approval: 2012 Due to the need to use VITEKTA with a protease inhibitor coadministered with ritonavir, consult prescribing information of -------------------------------INDICATIONS AND USAGE------------------------- coadministered protease inhibitor and ritonavir for their VITEKTA is a human immunodeficiency virus type 1 (HIV-1) integrase contraindications. (4) strand transfer inhibitor used in combination with an HIV protease inhibitor coadministered with ritonavir and with other antiretroviral -------------------------WARNINGS AND PRECAUTIONS---------------------- drug(s) indicated for the treatment of HIV-1 infection in antiretroviral Do not use with protease inhibitors coadministered with cobicistat. treatment-experienced adults. (1) (5.2) Do not use with other elvitegravir-containing drugs, including Limitations of Use: STRIBILD. (5.2) There are no comparative pharmacokinetic or clinical data Immune reconstitution syndrome: May necessitate further evaluation evaluating VITEKTA with cobicistat as single entities compared to and treatment. (5.3) STRIBILD®. (1) --------------------------------ADVERSE REACTIONS----------------------------- VITEKTA coadministered with protease inhibitors and cobicistat is The most common adverse drug reaction to VITEKTA (all grades) is not recommended. (1) diarrhea. (6.1) Coadministration of VITEKTA with dosage regimens or HIV-1 protease inhibitors other than those presented in Table 1 is not To report SUSPECTED ADVERSE REACTIONS, contact Gilead recommended. (1) Sciences, Inc. at 1-800-GILEAD-5 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
    [Show full text]
  • WO 2017/004012 Al 5 January 2017 (05.01.2017) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/004012 Al 5 January 2017 (05.01.2017) P O P C T (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 9/24 (2006.01) A61K 31/513 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, A61K 31/505 (2006.01) A61K 31/675 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (21) International Application Number: KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, PCT/US20 16/039762 MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (22) International Filing Date: PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, 28 June 2016 (28.06.2016) SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of regional protection available): ARIPO (BW, GH, (30) Priority Data: GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, 62/187,102 30 June 2015 (30.06.2015) US TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, 62/296,524 17 February 2016 (17.02.2016) US TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, (71) Applicants: GILEAD SCIENCES, INC.
    [Show full text]
  • Managing Drug Interactions in the Treatment of HIV-Related Tuberculosis
    Managing Drug Interactions in the Treatment of HIV-Related Tuberculosis National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention Division of Tuberculosis Elimination Managing Drug Interactions in the Treatment of HIV-Related Tuberculosis Centers for Disease Control and Prevention Office of Infectious Diseases National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention Division of Tuberculosis Elimination June 2013 This document is accessible online at http://www.cdc.gov/tb/TB_HIV_Drugs/default.htm Suggested citation: CDC. Managing Drug Interactions in the Treatment of HIV-Related Tuberculosis [online]. 2013. Available from URL: http://www.cdc.gov/tb/TB_HIV_Drugs/default.htm Table of Contents Introduction 1 Methodology for Preparation of these Guidelines 2 The Role of Rifamycins in Tuberculosis Treatment 4 Managing Drug Interactions with Antivirals and Rifampin 5 Managing Drug Interactions with Antivirals and Rifabutin 9 Treatment of Latent TB Infection with Rifampin or Rifapentine 10 Treating Pregnant Women with Tuberculosis and HIV Co-infection 10 Treating Children with HIV-associated Tuberculosis 12 Co-treatment of Multidrug-resistant Tuberculosis and HIV 14 Limitations of these Guidelines 14 HIV-TB Drug Interaction Guideline Development Group 15 References 17 Table 1a. Recommendations for regimens for the concomitant treatment of tuberculosis and HIV infection in adults 21 Table 1b. Recommendations for regimens for the concomitant treatment of tuberculosis and HIV infection in children 22 Table 2a. Recommendations for co-administering antiretroviral drugs with RIFAMPIN in adults 23 Table 2b. Recommendations for co-administering antiretroviral drugs with RIFAMPIN in children 25 Table 3. Recommendations for co-administering antiretroviral drugs with RIFABUTIN in adults 26 ii Introduction Worldwide, tuberculosis is the most common serious opportunistic infection among people with HIV infection.
    [Show full text]
  • Tenofovir Alafenamide Rescues Renal Tubules in Patients with Chronic Hepatitis B
    life Communication Tenofovir Alafenamide Rescues Renal Tubules in Patients with Chronic Hepatitis B Tomoya Sano * , Takumi Kawaguchi , Tatsuya Ide, Keisuke Amano, Reiichiro Kuwahara, Teruko Arinaga-Hino and Takuji Torimura Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, Fukuoka 830-0011, Japan; [email protected] (T.K.); [email protected] (T.I.); [email protected] (K.A.); [email protected] (R.K.); [email protected] (T.A.-H.); [email protected] (T.T.) * Correspondence: [email protected]; Tel.: +81-942-31-7627 Abstract: Nucles(t)ide analogs (NAs) are effective for chronic hepatitis B (CHB). NAs suppress hepatic decompensation and hepatocarcinogenesis, leading to a dramatic improvement of the natural course of patients with CHB. However, renal dysfunction is becoming an important issue for the management of CHB. Renal dysfunction develops in patients with the long-term treatment of NAs including adefovir dipivoxil and tenofovir disoproxil fumarate. Recently, several studies have reported that the newly approved tenofovir alafenamide (TAF) has a safe profile for the kidney due to greater plasma stability. In this mini-review, we discuss the effectiveness of switching to TAF for NAs-related renal tubular dysfunction in patients with CHB. Keywords: adefovir dipivoxil (ADV); Fanconi syndrome; hepatitis B virus (HBV); renal tubular Citation: Sano, T.; Kawaguchi, T.; dysfunction; tenofovir alafenamide (TAF); tenofovir disoproxil fumarate (TDF); β2-microglobulin Ide, T.; Amano, K.; Kuwahara, R.; Arinaga-Hino, T.; Torimura, T. Tenofovir Alafenamide Rescues Renal Tubules in Patients with Chronic 1.
    [Show full text]
  • DESCOVY, and Upon Diagnosis of These Highlights Do Not Include All the Information Needed to Use Any Other Sexually Transmitted Infections (Stis)
    HIGHLIGHTS OF PRESCRIBING INFORMATION once every 3 months while taking DESCOVY, and upon diagnosis of These highlights do not include all the information needed to use any other sexually transmitted infections (STIs). (2.2) DESCOVY safely and effectively. See full prescribing information • Recommended dosage: for DESCOVY. • Treatment of HIV-1 Infection: One tablet taken once daily with or ® without food in patients with body weight at least 25 kg. (2.3) DESCOVY (emtricitabine and tenofovir alafenamide) tablets, for • HIV-1 PrEP: One tablet taken once daily with or without food in oral use individuals with body weight at least 35 kg. (2.4) Initial U.S. Approval: 2015 • Renal impairment: DESCOVY is not recommended in individuals with WARNING: POST-TREATMENT ACUTE EXACERBATION OF estimated creatinine clearance below 30 mL per minute. (2.5) HEPATITIS B and RISK OF DRUG RESISTANCE WITH USE ----------------------DOSAGE FORMS AND STRENGTHS--------------------­ OF DESCOVY FOR HIV-1 PRE-EXPOSURE PROPHYLAXIS Tablets: 200 mg of FTC and 25 mg of TAF (3) (PrEP) IN UNDIAGNOSED EARLY HIV-1 INFECTION See full prescribing information for complete boxed warning. -------------------------------CONTRAINDICATIONS------------------------------­ DESCOVY for HIV-1 PrEP is contraindicated in individuals with Severe acute exacerbations of hepatitis B (HBV) have been unknown or positive HIV-1 status. (4) reported in HBV-infected individuals who have discontinued products containing emtricitabine (FTC) and/or tenofovir -----------------------WARNINGS AND PRECAUTIONS-----------------------­ disoproxil fumarate (TDF), and may occur with • Comprehensive management to reduce the risk of sexually discontinuation of DESCOVY. Hepatic function should be transmitted infections (STIs), including HIV-1, when DESCOVY is monitored closely in these individuals.
    [Show full text]